Clinical updates, including trial initiations, enrollment status and data readouts and publications: Amniox, Guardant Health.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aileron, Antibe, Belx, Biomarin, CTI, Gilead, GSK, Histogen, Iterum, Lineage Cell, Merck, Mesoblast, Moderna, Novartis, Novus, Ocugen, Pfizer, TLC.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Biocept, Caris Life Sciences, Creatv Microtech, Foundation Medicine, Hesperos, Myriad, Personalis, Sengine Precision Medicine, Tiziana Life Sciences.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Achilles, Adverum, Aveo, Bio-Path, BMS, Chiesi, Corvus, Eloxx, Galera, Janssen, Minerva, Molecular Partners, Myovant.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Livanova.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Akcea, Apellis, Atriva, Calcimedica, Enlivex, Genentech, Genmab, I-Mab, Ionis, Iovance, Neurotrope, Oncopeptides, Partner Therapeutics, Windmil, Zai.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Altapure, Biodesix, Biotronik, Clinical Genomics, Procept Biorobotics, Roche.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Adamis, Aileron, Alucent, Auris, Biolinerx, Compugen, Cytovation, Genentech, GT, Ironwood, Macrogenics, Mersana, Mina, Nascent, Novartis, NS Pharma, Radius, Transcenta, Vir, Zynerba.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Antisense, Arch Biopartners, Covis, Daiichi Sankyo, Diffusion, Incyte, Mezzion.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Freenome, Lucence, Oncolytics Biotech, Orteq Sports Medicine.